Esperion Q3 revenue up 69% on prescription volumes
Overview
Esperion Q3 2025 total revenue grows 69% yr/yr to $87.3 mln
Net income for Q3 missed analyst expectations
Reached settlement with Dr. Reddy's to delay generics until 2040
Outlook
Esperion expects sustainable profitability beginning in Q1 2026
Company reiterates 2025 operating expenses forecast of $215 mln to $235 mln
Esperion anticipates bempedoic acid inclusion in U.S. guidelines in early 2026
Result Drivers
U.S. PRESCRIPTION VOLUME - Increased U.S. prescription volume and expanded payer coverage drove revenue growth
SETTLEMENT AGREEMENT - Settlement with Dr. Reddy's prevents generic competition until 2040, supporting market leadership
GUIDELINE INCLUSION - Bempedoic acid's inclusion in European guidelines expected to boost utilization
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Product Sales | $40.66 mln | ||
Q3 Net Income | Miss | -$31.33 mln | -$14.50 mln (5 Analysts) |
Q3 Operating Income | Miss | -$9.96 mln | -$1.53 mln (4 Analysts) |
Q3 Basic EPS | -$0.16 | ||
Q3 Operating Expenses | $97.27 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Esperion Therapeutics Inc is $4.00, about 26.5% above its November 5 closing price of $2.94
Press Release:
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.